Erectile dysfunction (ED) is a prevalent medical condition affecting 18 million men and their sexual partners in the United States alone. In the majority of patients, ED is related to alterations in the flow of blood to or from the penis. Undeniably, significant progress has been made in understanding the multifactorial mechanisms that modulate erectile capacity and predispose one to ED, and this, in turn, has led to the availability of more effective treatment options. Nonetheless, all current therapies have untoward side effects, and moreover, there are still no satisfactory treatments for many patients with ED. Further enhancements in the treatment of ED would logically result from both early intervention and more detailed mechanistic insight into the characteristics of the disease process per se. This fact underscores the importance of improved understanding of the initiation, development and progression of ED. However, to do so requires longitudinal studies on animal models that more closely approximate the corresponding clinical features and time course of human disease. The goal of this report is twofold. First, to provide a brief general overview of the applicability of commonly used animal models for the study of ED. The second and primary goal is to highlight the scientific rationale for using non-human primates to evaluate the impact of atherosclerosis-induced vascular disease on the penile and systemic circulatory systems. This latter goal seems especially relevant in light of the recent literature documenting a link between ED and systemic vascular disease, a finding that has major implications in an aging US male population consuming a high fat diet. Keywords: animal models; atherosclerosis; non-human primates; vascular disease INTRODUCTION Erectile dysfunction (ED) is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance.
INTRODUCTION
Erectile dysfunction (ED) is defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. 1 --4 ED often has profound effects on intimate relationships, quality of life and overall self-esteem, causing serious distress and prompting men to seek medical attention. The economic impact of ED is multifaceted, with direct costs that include physician evaluation, pharmacotherapy and diagnostic testing, and indirect costs that include lost time at work, lost productivity and effects on the man's partner, family and coworkers. The Massachusetts Male Aging Study indicates that the prevalence of ED increases sharply with age. ED of some degree of severity is observed in 39% of men aged 40 years and in 67% of men aged 70 years. 2 The mechanistic basis for ED is complex and multifactorial, involving disruptions in neural, vascular and/or hormonal signaling. 5 --7 Research on central and peripheral neural pathways, as well as on local regulation of penile erection (that is, corporal and arterial smooth muscle and endothelium) is progressing rapidly. However, in the majority of patients, the final common pathology is alterations in the flow of blood to and from the penis. In this regard, the key neurotransmitters, local neurohumoral pathways and other regulatory mechanisms responsible for the local control of penile blood inflow and egress have been identified. 8 --13 This basic science information has been extensively leveraged and has clearly resulted in the development of more effective treatment options. Nonetheless, despite the improved efficacy of current therapies, they remain insufficient to address growing patient populations, such as those with diabetes and metabolic syndrome. In addition, increasing awareness of the adverse side effects of commonly prescribed medications on sexual function provides a rationale for developing new treatment strategies. 7,14 --17 Although ED has psychogenic components, it is typically associated with atherosclerosis and other modifiable risk factors, such as dyslipidemia, smoking, hypertension, diabetes mellitus, physical inactivity, depression and obesity. In all, the etiology of roughly 85% of organic ED patients can be attributed to atherosclerotic vascular disease, diabetes or medications commonly used to treat cardiovascular disease (CVD), such as thiazide diuretics and a-blockers. 5 --7,18,19 When viewed in this context, ED is clearly a prevalent vascular disorder thought to share common pathological features/mechanisms with systemic CVD (that is, coronary vascular disease), such as endothelial dysfunction. 4, 5 In fact, a burgeoning literature is now available that suggests that ED may be an early marker (biomarker) for atherosclerosis, increased cardiovascular risk and subclinical systemic vascular disease. 20 The emerging awareness that ED may provide a potentially valuable barometer/index for vascular health and occult CVD is an experimentally testable hypothesis that presents a unique opportunity to improve preventive cardiovascular health in all men, and particularly in high-risk and underserved minority populations. Moreover, the identification of predictable vascular antecedents to ED would have even further reaching implications with respect to prophylaxis for male vascular health and erectile capacity/sexual function throughout the lifespan. To do so requires detailed longitudinal studies of the incidence and interrelationships of penile and systemic vascular function as well as disease initiation and progression. However, such studies have not, and in fact cannot, be practically or ethically conducted in humans. Therein lays the importance of implementing animal models that more closely approximate the corresponding clinical features and time course of human disease. Given the increasing prevalence of vascular disease and the ever-advancing age of the world population, longitudinal studies of the impact of vascular disease on the systemic and peripheral vascular erectile pathways seem especially prudent.
As such, the overall goal of this report is twofold. First, to provide a brief general overview of the applicability of commonly used animal models for the study of ED. This is clearly relevant to new target identification for the treatment of ED. In fact, much of the therapeutic knowledge gained in this area relates to morphological and pharmacological studies conducted in commonly used experimental animal models (for example, rodents and rabbits), in which desired perturbations could be achieved and responses monitored in a reasonably meaningful way. However, it is important to note that the results of such investigations must be placed in proper context in light of the important differences between humans and the species investigated, with respect to the structure and function of the genital organs as well as the associated sexual behavior(s). In this regard, the second and primary goal of this report is to highlight the scientific rationale for using non-human primates (NHPs), in particular, to evaluate the impact of atherosclerosis-induced vascular disease on the penile and systemic circulatory systems. As will be reviewed in detail herein, the NHP provides an excellent surrogate for human studies that is nominally superior to other animal models for evaluating the long-term impact of vascular disease on erectile and systemic vascular function.
We begin this report with a focus on the need for new mechanistic insight and therapeutics to address the increasing medical burden that penile and systemic vascular disease will have in an aging US male population consuming a high fat diet.
ANIMAL MODELS
Before a discussion of the animal models, it is worth pointing out that the most frequently used end point for assessing erectile function, in any model, is the recording of intracavernosal pressure (ICP). In this regard, both electrical stimulation of the cavernous nerve and administration of pharmacological agents have been studied. 7, 21, 22 Less commonly, telemetric studies on freely moving animals 23 have also been reported. Furthermore, ICP can be recorded in both conscious and anesthetized animals, and available electronic data capture systems allow various aspects of the ICP response to be measured and recorded. 24 Typically measured end points include the basal ICP, peak ICP, plateau ICP, time to erection and detumesence time, duration of response, area under the ICP time response curve and the number of erections observed in a given time period. These parameters may be used to quantify the different phases and quality of the ICP response as well as the impact of disease and the effect of the actions of drugs upon them. Such investigations can be conducted in most animal models. However, other aspects of sexual function, which may have translational value, may not be possible to study in, for example, rodent and rabbits.
Since the causes of ED are multifactorial, several animal models have to be used to gain increased mechanistic insight into ED pathology and to identify potentially novel molecular targets for therapy.
Rat models of ED The most common animal model used for ED studies is the rat. In fact, studies in rats have been critical to the identification of many of the mechanisms thought to contribute to ED. The major advantages of the rat model include convenient size (100 --600 g), availability of facilities to house rats in most institutions, low cost compared with large animal species (10 --100-fold less), welldefined methods for evaluating the extent of ED, standardized sexual behaviors and defined modeling protocols for risk factors contributing to ED (hypercholesterolemia, diabetes and hypertension). Additionally, laboratory rats (depending on species) live between 1 and 3 years, permitting evaluations of aging on ED function and treatments.
For in-vivo evaluation of erectile function in rats, most laboratories employ either apomorphine-induced erectile response or electrical field stimulation. 25 Administration of apomorphine causes characteristic yawning and stretching responses and engorgement of the glans penis. Any alteration in this response implies ED caused by derangement in the paraventricular nucleus-penile axis. 6, 7 In this sense, sexual behavior is easily observed and quantifiable. However, the rapid nature of the erectile response with this approach prevents acquisition of information concerning the quality and success of erections.
Erectile function in rats can be also be quantified using another approach, where pharmacological administration of a vasoactive agent and/or electrical field stimulation of the major pelvic ganglion/cavernous nerve are used to quantify neuronally induced erectile function in anesthetized rats. Use of these techniques, as well as various modifications, has significantly increased our knowledge of the role/impact of neurotransmitters, 26 castration and androgen maintenance, 27 premature ejaculation, 28 cavernous nerve injury, 29 --32 internal artery ligation, 33 gene therapy, 34 diabetic models (for example, BB/WORdp, BBZ/ WORdp, and Zucker obese/diabetic rats), 35 --37 hypercholesterolemia, 38 Peyronie's disease 39 and aging (for example, the BrownNorway model and others) 40, 41 on erectile capacity/function. More recent studies have examined the role of vascular structure and function of the pudendal artery in the control of erection in rats. 42 Therefore, rats can be used to assess many of the causes of, and potential treatments for, ED in a relatively short time frame and at a reasonable cost.
Rats have also been used extensively to identify potential pharmacological targets for the treatment of ED. 43, 44 These include, for example, dopamine receptors 45 and oxytocin receptors. 46, 47 With respect to peripheral pharmacological targets for ED, rat models have included studies of norephinephrine and a-adrenoceptors, 48 acetylcholine and cholinergic receptors. 49 --51 These receptors have been shown to be critical to normal erectile function. However, the distribution of a1-adrenoceptors in the penis and systemic vessels may not be the same in rats and humans 52 and may not respond similarly to adrenoreceptor stimulation.
Additionally, rats have been used to determine the potential role of peripheral endothelin receptors, 53 dopamine receptors (D1 and D2), 54, 55 serotonin receptors, 56 prostanoid receptors, 57 endocannabinoids, 58 the nitric oxide (NO)/guanylate cyclase pathway 59 --61 and the RhoA/Rho-kinase pathway 62 in the pathophysiology and treatment of ED. The role of ion channels (chloride channels, potassium channels) in modulating erectile function has also been well established in the rat model. 44, 63, 64 Again, because these targets are critical to normal erectile function, they are of potential importance for treatment in ED patients.
Modulation of other relevant pathways has also been proposed as potential treatments for ED, and these have included rats studies of neuromodulation following nerve injury and application of various nerve growth factors, 65, 66 as well as vascular endothelial growth factor to induce/enhance angiogenesis. 67 Rats have also been used to identify the role of specific cell types found in the penis in the pathogenesis of ED. Studies of endothelial cells and endothelial cell modification include cloning and insertion of NO synthase, 68, 69 endothelial function in hypercholesterolemia 70 and vascular endothelial growth factor. 71 Rat studies examining the role of smooth muscle cells in ED include gene insertion of calcium-sensitive Maxi-K channels 72, 73 and the cAMP pathways. 74 The preclinical work with the Maxi-K channel has, in fact, led to the first human trial for a gene therapy-based approach to ED. 72 As such, rats have been used to define the important pathways contributing to normal and abnormal erectile function and to identify one of the most commonly prescribed classes of drugs in the United States (cGMP phosphodiesterase inhibitors) for ED.
Despite the obvious utility of the rat model for studying the pathophysiological basis for ED, as well as for the identification of relevant therapeutic targets, there are still limitations to this model. For example, while mammals share the same reproductive system, including the regulatory hypothalamic system that releases gonadotrophin hormones in pulses, and the resulting pulses of ovarian hormones (estrogen and progesterone), the two species vary significantly in the functional details. Female rats come into heat every 4 --5 days and there is no defined breeding season. Actual mating behavior in rats, although well characterized, is brief and hard to capture and quantify. Also, pheromones have an important role in sexual activity. 50, 51 Thus, the triggering mechanism (smell) is an important factor in activating sexual desire and proper mating. This is not the case in primate species where sight and touch are an important stimulus for erection and successful mating. While this difference has little effect on basic mechanisms of erection and ED, it may effect treatment options if they affect the parts of the brain controlling sight and touch.
Rats have also been used to study the effects of aging on ED. 40, 41, 74 However, the lifespan of a laboratory rat is relatively short (1 --3 years), which accelerates any aging effects and shortens the time for longitudinal studies of aging on ED. Probably, the most important limitation of rats is in relation to vascular-associated ED---which will be discussed in more detail in the second part of this review. This is especially true when hypercholesterolemia and atherosclerosis are the major contributing factors. Hypercholesterolemia in non-genetically engineered rats is produced primarily by changes in high-density lipoprotein cholesterol (HDL-C). This is vastly different from primates in whom cholesterol-rich diets produce increases in low-density lipoprotein cholesterol (LDL-C) and reductions in HDL-C. 75 There have been a number of genetic models developed recently, but genetic models offer limited direct translatability. Similarly, normal rats are quite resistant to the development of atherosclerosis (because of the HDL-C effect) but can be induced to develop atherosclerosis in conduit arteries by feeding them large amounts of cholesterol in their diet and/or supplementing their diets with thiopropyluracil to create hypothyroidism. 76, 77 There are genetic variants of atherosclerosis-prone rats including Fatty Zucker rats and Corpulent rats. 76, 77 Even in the genetic variants that are prone to develop atherosclerosis, the atherosclerosis is more centrally distributed (in conduit arteries and aorta) and results in rats have generally failed to predict clinical success. 76, 77 However, these last two examples are also prone to diabetes, another risk factor for peripheral atherosclerosis. While some rat studies have used arterial occlusion to model reduced blood flow to the penis, overt occlusion is rarely seen in peripheral artery disease, 76 where the resulting pathology is most likely caused by impaired vascular function and capacity rather than fixed lesion stenosis.
In summary, rats have been invaluable in identifying potentially important pathophysiological mechanisms of ED, and treatment modalities have been developed based largely on studies done in this species. In addition, their reasonable cost, well-defined sexual behavior and widespread feasibility due to their husbandry make them an attractive animal model. However, once studies extend beyond basic mechanisms, especially with respect to atherosclerosis-related ED, the rat model has limitations that could confound the translatability of the results obtained in rats to human beings. Despite these shortcomings, the rat model remains a powerful tool for identifying new approaches for treating ED.
Mouse models of ED There is increasing use of mice as animal models of ED. 78, 79 They share many of the same advantages as rats, but have the added benefit of supplying numerous genetic models that can be used to probe the molecular basis of erectile physiology as well as mechanisms responsible for ED. For example, knockout mice have been used to study the role of tumor necrosis factor-a in corpora cavernosa relaxation. 80 Adenosine actions on ED have been explored in obese and type 2 diabetic db/db mouse 81 as well as in A2B receptor-knockout mice. 82 Mouse models of NO pathway disruption have been critical in defining the role of vasodilators as targets for the treatment of ED. 83 --86 The cGMP kinase I-deficient mouse has also been used to better understand the role of smooth muscle cells in the pathogenesis of ED. 87 The important role of the Maxi-K channel has also been verified using a mouse model lacking this large-conductance, calcium-activated channel. 88 As such, the mouse serves as a very powerful 'proof of concept' model to further exploration of pathways that may lead to a better understanding of the pathogenesis of ED as well as specific treatment targets.
Unfortunately, despite the advantages of molecular genetic approaches, mice still have limitations as models of ED, again, particularly with respect to vascular disease. For example, similarly to rats, mice are relatively short lived (1 --2 years) and characteristically resistant to CVD, reducing their applicability for aging and vascular-related ED of peripheral vessels. Furthermore, much of their sexual activity and receptivity is based on smell. Which again is in contrast to that of primates, where the primary stimuli are sight and touch. However, there are more mouse models of hyperlipidemia and atherosclerosis than in rats, including ApoEknockout mice, LDL receptor-knockout mice 89 and the db/db mouse that is prone to develop hypertriglyceridemia. 89 These mice, especially ApoE-knockout mice, develop more widely distributed centralized atherosclerosis than in rats, but still not approaching that seen in primates. Mice, while more cost effective than rats, are limited by being even smaller than rats and harder to instrument. If the goal of the experiments is to examine the effects of peripheral artery disease on ED, or the complex interactions and interrelationships that may exist with respect to the systemic vasculature, then the mouse models present significant technical barriers to rigorous physiological investigations. Moreover, murine sexual behavior does not approximate the sophisticated primate-like triggers for sexual function and behavior. Nonetheless, the mouse model still provides a unique opportunity to examine specific pathophysiological pathways that contribute to ED.
Rabbit models of ED Rabbits are the most common non-rodent model used for ED research. Like rodents, most institutions have, or can develop rabbit facilities and have the staff to oversee their care and husbandry. Rabbits are more expensive than rodents, but the costs are still 10 --50 times less than larger species (for example, dogs and NHPs). Rabbits have been used to study cannabinoid receptors and endogenous vascular growth factor-derived peptides as central nervous system targets for ED therapy. 90 --92 Rabbits have also been used to identify peripheral targets for therapy including the acetylcholine and cholinergic receptor pathways, 92, 93 62, 99 Because of their larger size compared with rodents, rabbits have also been effectively used to study some vascular aspects of ED, including oxidative stress, ischemia and atherosclerosis. 100 --107 Furthermore, because of the existence of Watanabe hyperlipidemic rabbits, they have been used to study the interaction of hyperlipidemia and vasculogenesis on ED. 108 --111 These studies include testing the role and potential efficacy of vascular endothelial growth factor 108, 110 and basic fibroblast growth factor 109,111 on ED. Rabbits have also been used extensively in therapies for ED including the use of SeveranceSecret cream (a topical agent derived from the extracts of nine natural products-supplements; Ginseng Redix Alba, Angelicae Gigantic Radix, Cistanchis Herba, Zanthoxylli Fructs, Torlidis Semen, Asiasari Radix, Caryophylli Flos, Cinnamoni Cortex and Bufonis Veneum) 112 and for tissue engineering approaches including phallic reconstruction. 113, 114 In this sense, rabbits offer the advantages of being able to measure specific physiological pathways while also providing an opportunity to explore more 'human-like' atherosclerotic vascular disease.
The reproductive cycles of rabbits are somewhat like rodents in that they come into heat frequently and smell is an important stimulus for mating activity. However, they tend to be seasonal breeders and sight (genital appearance) plays a larger role in their sexual behavior---compared with rodents. As mentioned, there are well-established rabbit models of atherosclerosis; and furthermore, the hyperlipidemia in rabbits is LDL-C based, although mostly in the very low-density lipoprotein cholesterol fraction. 80 --83 However, the nature of the atherosclerosis is different than that of primates in that the atheromas are very macrophage rich (little sclerosis). Like rodents, their atherosclerosis is more centralized to the major conduit arteries unless other risk factors are presents such as induced diabetes. 107, 110, 111 Overall, rabbits are an intermediate model in cost, size and applicability between rodents and large animal species for the study of ED.
Large animal models of ED A much smaller number of investigations have been conducted using large animal species (that is, dogs and NHPs) in the exploration of erectile physiology and ED. This is due to their cost (many fold higher purchase and per diem costs), lack of genetic models to research-specific pathways, complex facility and husbandry needs, and ethical concerns. Nonetheless, of the large animal species, there is a publication using isolated vessels from horses to explore the potential role of adrenoceptors in the pathogenesis of ED. 115 In addition, because of the overt similarities in the anatomy and physiology of the dog and human penis (size that permits evaluation of both frequency and quality of erections, arteries supplying the penis with blood, and relative collagen/muscle content, as well as neural innervation), 116 --118 there are also a few dog studies that have examined the role of ATP, adenosine and adenosine receptors in the pathogenesis and treatment of ED. 119 --121 In addition, the dog model has been used to evaluate the role of vasoactive intestinal polypeptide, acetylcholine 121 as well as forskolin and the cAMP system in modulating erectile capacity/function. 122 Dogs have a longer lifespan (12 --16 years) that is roughly equivalent (in life stages) to that of human beings. Their mating activity is well documented, easier to observe, and is based on both sight and smell. However, canines are not prone to atherosclerotic disease, and thus, are not used in atherosclerosis-related ED.
Studies in NHPs are also quite rare, but several seminal studies have explored various aspects of the pharmacological, intracellular and neural mechanisms of penile erection in NHPs. 123 --129 In addition, Wagner examined the effects of pinacidil on penile erection in vivo and penile corporal tissue relaxation in vitro. Another study evaluated atherosclerosis-induced ED. 130 More recently, the expression of endocannabinoids on corporal tissue from NHP has been investigated. 58 Finally, the first gene therapy study on NHPs was recently conducted. 131 In this investigation, animals were subjected to a single intracavernous injection of the human Maxi-K channel a-subunit (that is, intracavernous injection) following the development of atherosclerosis-induced erectile impairment. In short, Maxi-K gene transfer was shown to elicit a rather dramatic improvement in erectile function and sexual behavior in these atherosclerotic male NHPs. 131 The importance of this investigation is that it documents that a gene therapy approach already verified in preclinical studies in rodents, and furthermore, shown to be safe in humans with ED, also has applicability in an animal model that recapitulates many of the important characteristics and course of the erectile and vascular disease that occurs in a large proportion of impotent men.
A summary of species characteristics that make different animal models unique to studies of ED are depicted in Table 1 . In general, as one moves up from smaller animal models to larger animals Species comparisons of characteristics and risk factors of each species as relevant animal models of ED. Plus signs (+) reflect the relative abundance, amount or presence of the characteristics. 'Erection stimuli' refer to the stimuli sensed by the male that stimulates erection and sexual activity. 'Ability to measure erection qualityy.' refers to the ability to measure not only the presence of an erection, but also the ability to measure the quality of erection, the success of intromission and ejaculation.
there are fewer facilities able to house the larger animals, the cost/ animal goes up precipitously, and one loses the ability to study individual genes and pathways that may contribute to the pathogenesis of ED. However, the use of larger animals permits more rigorous studies requiring instrumentation of the end organ tissues/targets, for example, catheter-based functional measurements of relevant peripheral vessels such as the coronary and, animals closer to human beings along the phylogenetic tree, and the capability of studying more naturally occurring risk factors (in contrast to genetic models). This is particularly true for atherosclerotic vascular disease. A discussion of the applicability of NHPs to vascular ED is discussed in the subsequent paragraphs.
NHP MODEL OF ATHEROSCLEROTIC VASCULAR DISEASE
Despite their cost, NHPs have some potential advantages over smaller animals, again, most importantly, with respect to atherosclerosis-induced vascular-mediated ED. In particular, when macaque monkeys are fed a moderately atherogenic diet, they, like human beings, develop dyslipoproteinemia characterized by increased LDL-C and reduced HDL-C 132,133 within 1 --3 months. After consuming these diets for 5 --6 months, fatty streaks develop consistently in central locations (larger conduit arteries such as the aorta, carotid, common iliac and proximal coronary arteries) and to a lesser frequency in peripheral arteries (external and internal iliac arteries). As the atherogenic diets continue to be consumed for an additional 12 months, frequency and consistency of fatty streaks increases in the peripheral arteries (external and internal iliac, femoral, brachial, intestinal), while fatty streaks progress into fibrofatty plaques in centralized locations. After consuming atherogenic diets for 4 years, fibrofatty plaques extend into the internal pudendal and penile arteries and are associated with the appearance of ED in these animals. 130 From there, lesions continue to develop into complicated atheromas with large necrotic cores, extensive neovascularization, accumulation of large numbers of inflammatory cells along the margin of the necrotic cores and thin fibrous caps. These lesions can rupture and lead to myocardial infarction at about the same prevalence and gender distribution as human beings. 134 Furthermore, serum expression of inflammatory markers often associated with atherogenesis and impaired vascular function occurs early in the atherogenic process in NHP and mirrors those appearing in humans. 135 Characteristics of NHPs that make them important animal models for ED research are fourfold: (1) males respond to a complex combination of visual and behavioral (rather than olfactory) signals from the female that initiate erection and sexual contact. 130 This is most similar to the stimuli that initiate human sexuality; (2) the ability to quantify mating behavior (sexual interest, quality of erection, time of coitus, intromission and ejaculation) occurs over a longer time frame than in rodents and rabbits and is the most 'human-like' of these species; (3) the general male behavior and feeling of well being, and pre-and post-coital behavior can be quantified in NHPs and is not dissimilar to that human beings (for example, post-coital desire of the male for distance from the female); and (4) if vascular etiology and improved prevention and treatment of ED are the primary goal of the research, then no other animal model naturally develops all the lesion characteristics (iliac artery, femoral artery and pudendal artery atherosclerosis) and functional changes (large artery and resistance-size artery vasodilator dysfunction) associated with peripheral artery disease as well as NHPs. The size of these animals and the associated vascular and erectile tissues also aid in supplying tissues for multiple endpoints.
ED AS HARBINGER OF INCREASED CARDIOVASCULAR RISK
A recent important observation, specifically relevant to the utility of NHPs to basic and translational ED research, is that patients with ED may also be at increased risk of coronary heart disease. 136 --138 It is reported that both the structural and functional pathologies that exists in the nutrient arteries in the penis that lead to ED are also present in the coronary arteries. Both of these pathologies can lead to vascular occlusion and myocardial infarction. Therefore, the presence of vascular ED may be a harbinger of future coronary events.
The exact pathogenesis of atherosclerosis-induced vascular ED is not entirely clear. However, it is known that functional changes of arteries are associated with impaired vasodilatation and enhanced constriction of arteries. 139 Functional changes can precede the development of atherosclerotic lesions and are enhanced by diabetes, cigarette smoking, hyperlipidemia and hypertension. 139 At the cellular level, endothelial dysfunction results in impaired bioavailability of NO. Oxidative stress (that is, free radical damage), which interferes with the NO pathway and also is directly toxic to the endothelium, is also a causal factor of the vascular damage associated with preclinical/asymptomatic disease. 136 --140 Free radical damage and impaired bioavailability of NO also result in increased adhesion and aggregation of platelets and neutrophils and the release of vasoconstrictor substances, 141 thus further reducing blood flow to the end organ(s).
Pertinent to ED, the penis is a richly vascularized organ, and penile erections are, in large part, a neurovascular event mediated by the NO pathway. More specifically, upon sexual stimulation, NO is released from both the vascular endothelium of the penis and the autonomic cavernous nerve terminals, leading to activation of soluble guanylyl cyclase, increases in the cGMP and relaxation of arterial and corporal smooth muscle in the penis leading to a robust increase in penile blood flow. 142, 143 In this regard, there are several lines of evidence suggest that impaired endotheliummediated dilation occurs early in atherogenesis. 144 --150 In fact, impaired endothelium-mediated dilation may occur during the initial stages of dyslipoproteinemia. 151 Importantly, impaired endothelium-mediated dilation has been shown to be prognostic of coronary heart disease, even in the early stages. 151 --153 Thus, the presence of peripheral endothelium-mediated dilation is consistent with our current understanding of the pathogenesis of atherosclerosis, whereby endothelial dysfunction occurs early and contributes to disease progression systemically. Endothelial dysfunction is not an isolated insult but rather a manifestation of early atherosclerotic disease. Similarly, vasculogenic ED is usually a sign of endothelial dysfunction and thus a marker of systemic atherosclerosis.
Extant data concerning the physiological characteristics of the pudendal artery and the small diameter cavernosal arteries 154 suggest that the alterations in the penile vascular bed may be a sensitive indicator of systemic vascular disease. 155 Consistent with this supposition, recent reports have emphasized the importance of better understanding the contribution(s) of altered penile vascular structure/function to ED-related CVD. 156, 157 In this scenario, ED may result early on, for example, from atherosclerosis-induced alterations in the penile vascular bed (that is, the pudendal and cavernosal arteries). These changes can occur by remodeling/occlusion (that is, structural vascular ED), by impairment of endothelial-dependent and/or endothelium-independent smooth muscle relaxation (that is, functional vascular ED), or by a combination of both structural and functional factors. ED is clearly, in part, an occlusive---whether structural or functional---atherosclerotic disease. With respect to ED being a sentinel or harbinger of future coronary heart disease, the rationale is as follows. Because the smaller arteries of the penis are nominally more susceptible to atherosclerotic occlusion than the larger vessels of the heart and limbs 158, 159 atherosclerotic lesions may first become clinically manifest in the penile arteries. Investigators have hypothesized that occlusion of the smaller penile arteries (1 --2 mm in diameter) occurs well before occlusion of the coronary (3 --4 mm) or peripheral (5 --7 mm carotid or 6 --8 mm femoral) arteries. 154, 155 This artery size/lumen occlusion hypothesis is one reason used to explain why the symptom of erectile difficulty occurs before other clinical vascular symptoms. 155 --158 Another explanation is that ED is also caused by functional vascular alterations, such as derangements in endothelial cell-to-cell junctions, diminished endothelial cell content or increased oxidative stress, all of which lead to decreased bioavailability of NO. 159 These are changes that appear to occur very early in the course of atherosclerosis in other vascular beds (for example, coronary and iliac arteries)---before the development of atheroma. Taken together, available evidence supports the general hypothesis that the early symptom of erectile difficulty (that is, inability to maintain rigidity) caused by endothelial cell and smooth muscle dysfunction probably occurs before the development of structural, occlusive penile arterial disease, and may therefore be one of the first signs of systemic vascular disease.
Certainly, the concept that ED begins as a functional, nonobstructive process early in the course of cardiovascular risk factor development and atherosclerosis is relatively new. Given that it is the lipid-rich minor lesions (o50% stenosis) in the coronary or peripheral arteries that are most likely to rupture with adverse clinical consequences, 160 detecting ED early in the cascade of atherosclerosis provides the best opportunity to modify risk factors and prevent occurrence of vascular events. Over time, the same systemic risk factors that contribute to functional ED seem likely to lead to the development of chronic occlusive CVD. The recognition of ED as a harbinger of coronary heart disease represents a remarkable opportunity for prevention, and understanding the time course of disease progression, in both the penile vasculature and the systemic circulation, and therefore, provides an enormous opportunity for the development of novel therapeutics for the treatment of both.
The enormity of the health problems associated with atherosclerosis-related vascular disease clearly makes this an attractive area of translational research associated with a significant unmet medical need---with respect to both general vascular health and sexual function in males. So, implementation of appropriate animal models is an absolutely prerequisite to scientific and clinical progress. If one compares animal species, the use of NHPs appears to be best suited to address this particular issue. As noted above, macaque species (for example, rhesus and cynomolgus) develop dyslipoproteinemia (increased LDL-C and reduced HDL-C) in response to consuming a moderately atherogenic diet. 60 Importantly for the study of ED, the lesions progress both centrally and into the peripheral vasculature (including internal iliac arteries, pudendal arteries and femoral arteries) and impaired vascular endothelial function occurs early in the fatty streak both in central and in peripheral arteries before the development of extensive central atheroma. 161 Table 2 summarizes the species differences in development of atherosclerotic vascular disease and underscores the importance of NHP as animal models of this disease.
SUMMARY
The use of animal models has been critical to our understanding of the pathophysiology of ED and in designing improved treatments for ED patients. Rodents have been used extensively and their strength is their cost, supply and ability to define the mechanisms contributing to ED. Many of the rodent models used in ED research are genetically engineered (especially mice) and their contribution to ED research has been invaluable. Rabbits seem to be the intermediate choice with respect to cost, supply and availability. Their lifespan is longer than rodents and they have been used for studies of vascular (atherosclerosis) causes of ED. Rabbits have also been used to define many of the mechanisms associated with the pathogenesis of ED. Their size also makes them applicable for regenerative medicine and tissue- Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL, very low-density lipoprotein cholesterol.
Species comparisons of atherosclerotic vascular disease. Plus (+) signs reflect the relative abundance of lesions in the peripheral vasculature. Plaque complications refer to large necrotic cores, presence of inflammatory cells, thin fibrous caps, neovascularization. Impaired vascular function refers to impaired smooth and endothelium-mediated dilation.
engineering approaches to ED. NHPs are expensive and require specialized housing and husbandry. However, their sexual triggering stimuli, behavior, and initiation, development and progression of atherosclerosis-induced vascular disease closely matches to that of human beings, and makes studies of vascular ED almost directly applicable to that of human beings.
